Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00008 | Val-Cit-PAB-MMAE | 644981-35-1 |
| Val-Cit-PAB-MMAE, a tubulin polymerase inhibitor, is a drug-linker conjugate for ADC. It contains an ADC linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE. | Inquiry | |
| BADC-00009 | DM1-SMCC | 1228105-51-8 |
| DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate, as a potent EGFR inhibitor and it overcomes resistant to EGFR. | Inquiry | |
| BADC-00010 | DM1-SPP | 452072-20-7 |
| DM1 with a reactive linker SPP, which can react with antibody to make antibody drug conjugate, as a potent EGFR inhibitor and it overcomes resistant to EGFR. | Inquiry | |
| BADC-00011 | DM4-SPDP | 2245698-48-8 |
| DM4 with a reactive linker SPDP, which can react with antibody to make antibody drug conjugate. DM4 can bind to tubulin at or near the vinblastine-binding site. | Inquiry | |
| BADC-00012 | DM4-SPDB | 1626359-62-3 |
| DM4 with a reactive linker SPDB, which can react with antibody to make antibody drug conjugate. DM4 can bind to tubulin at or near the vinblastine-binding site. | Inquiry | |
| BADC-00013 | MC-Val-Cit-PAB-MMAF | 863971-17-9 |
| MC-Val-Cit-PAB-MMAF is a potent tubulin inhibitor (MMAF), Val-Cit-PAB-MMAF is an antibody drug conjugate. | Inquiry | |
| BADC-00014 | Mc-MMAF | 863971-19-1 |
| Mc-MMAF is a protective group-conjugated MMAF, MMAF is an antitubulin agent that inhibit cell division by blocking the polymerization of tubulin and it has lower cytotoxic activity than MMAE. | Inquiry | |
| BADC-00016 | Vat-Cit-PAB-MMAD | 1415329-13-3 |
| Vat-Cit-PAB-MMAD is a protective group conjugated MMAD, MMAD is a toxin payload in antibody drug conjugate. | Inquiry | |
| BADC-00020 | DM1-SMe | 138148-68-2 |
| DM1-SMe is a potent maytansinoid microtubular inhibitor and an unconjugated DM1 as a mixed disulfide with thiomethane to cap its sulfhydryl group. DM1-SMe can be readily conjugate to the SH group of an antibody to form antibody-drug conjugate (ADC). . | Inquiry | |
| BADC-00021 | DM4-SMe | 796073-68-2 |
| DM4-SMe can be readily conjugate to the SH group of an antibody to form antibody-drug conjugate (ADC). . | Inquiry | |
| BADC-00022 | DM3-SMe | 796073-70-6 |
| DM3-SMe can be readily conjugate to the SH group of an antibody to form antibody-drug conjugate (ADC). . | Inquiry | |
| BADC-00025 | Mc-MMAE | 863971-24-8 |
| Mc-MMAE is a protective group conjugated MMAE, MMAE inhibits tubulin polymerization so that it inhibits cell division. | Inquiry | |
| BADC-00029 | MC-Val-Cit-PAB-MMAE | 646502-53-6 |
| MC-Val-Cit-PAB-MMAE is a potent tubulin inhibitor (MMAE), Val-Cit-PAB-MMAE is an antibody drug conjugate. | Inquiry | |
| BADC-00606 | Deruxtecan | 1599440-13-7 |
| Deruxtecan analog is a drug-linker conjugate for antibody-drug conjugate (ADC). Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody-drug conjugate. DS-8201a significantly suppressed tumor growth in an immunocompetent mouse model with human HER2-expressing CT26.WT (CT26.WThHER2) cells. DS-8201a is currently in clinical trials. | Inquiry | |
| BADC-00732 | MA-PEG4-vc-PAB-DMEA-duocarmycin SA | |
| MA-PEG4-vc-PAB-DMEA-duocarmycin SA is a drug-linker conjugate for ADC by using Duocarmycin SA (a potent antitumor antibiotic), linked via MA-PEG4-vc-PAB-DMEA. | Inquiry | |
| BADC-00742 | CL2A-SN 38 | 1279680-68-0 |
| CL2A-SN 38 is a drug-linker conjugate for ADC by using SN 38 (a DNA Topoisomerase I inhibitor), linked via CL2A. | Inquiry | |
| BADC-00745 | MA-PEG4-vc-PAB-DMEA-duocarmycin DM | |
| MA-PEG4-vc-PAB-DMEA-duocarmycin DM is a drug-linker conjugate for ADC by using Duocarmycin DM (a potent antitumor antibiotic), linked via MA-PEG4-vc-PAB-DMEA. | Inquiry | |
| BADC-00756 | DBCO-PEG4-vc-PAB-MMAF | |
| DBCO-PEG4-vc-PAB-MMAF is a drug-linker conjugate for ADC by using Monomethylauristatin F (MMAF, a potent tubulin polymerization inhibitor), linked via DBCO-PEG4-vc-PAB. | Inquiry | |
| BADC-01340 | Gly3-VC-PAB-MMAE | 2684216-48-4 |
| Gly3-VC-PAB-MMAE is a drug-linker conjugate for ADC consisting of a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). | Inquiry | |
| BADC-01404 | PNU159682-EDA | 2255344-14-8 |
| PNU159682-EDA is a drug-linker conjugate for ADC by using PNU159682 (a potent DNA topoisomerase II inhibitor), linked via EDA. | Inquiry |
